INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM

Stock Information for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
Journey Medical Corporation to Participate in September 2026 Investor Conferences
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.